<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: OrbiMed Advisors Israel II Ltd -->
          <cik>0001682093</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001720580</issuerCik>
      <issuerName>Adicet Bio, Inc.</issuerName>
      <secFileNumber>001-38359</secFileNumber>
      <issuerAddress>
        <com:street1>131 DARTMOUTH STREET</com:street1>
        <com:street2>3RD FLOOR</com:street2>
        <com:city>BOSTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02116</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-482-2333</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Israel Partners II, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Themis Trading LLC</name>
        <address>
          <com:street1>10 Town Square</com:street1>
          <com:street2>Suite 100</com:street2>
          <com:city>Chatham</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07928</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>40416</noOfUnitsSold>
      <aggregateMarketValue>264724.80</aggregateMarketValue>
      <noOfUnitsOutstanding>9596407</noOfUnitsOutstanding>
      <approxSaleDate>04/08/2026</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>09/15/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Merger</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>40416</amountOfSecuritiesAcquired>
      <paymentDate>09/15/2020</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Israel GP II, L.P. is the general partner of OrbiMed Israel Partners II, L.P. OrbiMed Advisors Israel II Limited is the general partner of OrbiMed Israel GP II, L.P.</remarks>
    <noticeSignature>
      <noticeDate>04/08/2026</noticeDate>
      <signature>/s/ Carl L. Gordon, Director, OrbiMed Advisors Israel II Limited, general partner of the general partner of OrbiMed Israel Partners II, L.P.</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
